Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Amgen and Adaptive Biotechnologies join a long list of drug and vaccine development partnerships to combat COVID-19

With the advent of COVID-19 reaching over one million cases worldwide, a concerted effort will be needed to approach this growing problem.  Drug development partnerships between companies that complement their areas of expertise will more rapidly facilitate research on this disease, says GlobalData. Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData, commented: “While past historical data […]
Read more

Intensive care units would experience severe strain from high-risk groups of COVID-19, says GlobalData

As the COVID-19 situation grows, intensive care units (ICUs) in hospitals have to handle more patients with severe cases of the virus. COVID-19 can be more severe for those individuals with pre-existing conditions such as diabetes, heart disease, chronic obstructive pulmonary disease (COPD), and asthma along with immune-compromised or older individuals. As Europe and the […]
Read more

Risk of severe COVID-19 faced by 330m people in the 9MM, says GlobalData

Coronavirus (COVID-19) has now spread across 184 countries with approximately 1.5 million total confirmed cases worldwide as of 09.04.2020; Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data and analytics company, offers her view on the current challenges facing the 9MM: “We now know that severe and critical forms of COVID-19 are more common in the elderly […]
Read more

COVID-19 social distancing measures will impede global RSV clinical development, says GlobalData

Following the introduction of social distancing measures, brought in to reduce the spread of COVID-19 across the globe; Emily Carter-Richardson, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on how this could impact the development of respiratory syncytial virus (RSV) vaccines: “The infection control measures of social distancing to prevent […]
Read more

HCV diagnosed incident cases will substantially increase following updated guidelines

According to new guidelines published by the US Preventive Services Task Force (USPSTF), hepatitis C virus (HCV) screening will now expand to include all adults ages 18 to 79 years, effectively replacing the 2013 recommendations which limited screening to only high-risk individuals and adults born between 1945 and 1965. With the expanded screening criteria, the number of truly diagnosed incident cases will substantially increase over the […]
Read more

Alexion to start Soliris in COVID-19 Phase II trial in next few days, says GlobalData

Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source familiar with the trial told Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda comments: “The source explained that the idea behind Soliris […]
Read more

US COVID-19 cases projected to increase 65% as risk of transmission likely to surpass Italy and Spain, says GlobalData

In the key markets most heavily affected by the coronavirus (COVID-19), case trends are expected to follow a low-risk forecast, with the exception of the US, according to GlobalData, a leading data and analytics company. Natasha Karim, Managing Epidemiologist at GlobalData comments: “Most countries have enforced strict quarantine and mitigation measures. As a result, confirmed […]
Read more

Combination therapies could help overcome limitations of ICIs for oncology indications, says GlobalData

While checkpoint inhibitors as monotherapies have fulfilled expectations in some indications, novel combinations are on the horizon in a broader range of cancers says GlobalData, a leading data and analytics company. The company’s latest report, ‘Immuno-oncology: Focus on Development and Opportunities in Immune Checkpoint Modulators’, reveals that developers are investigating new checkpoint targets to overcome some […]
Read more

COVID-19 pandemic has multitude of implications for cardiovascular and metabolic disorder space, says GlobalData

COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular (CV) and metabolic disorder (CVMD) category. The current uncertainty regarding treatment with certain CV drugs, the supply chain and clinical trials is also notable. Overall, the pandemic is already impacting the CVMD healthcare landscape, and leading data and […]
Read more
,

Coronavirus is prompting suppliers of all shapes and sizes to adapt and support the healthcare system

Thus far, the novel coronavirus (COVID-19) pandemic has surpassed 860,000 confirmed cases globally and while the economic impact is weighing heavily across sectors, organizations are exploring creative ways of how to combat the outbreak. The responses are not only fighting COVID-19, supporting the general public and propping up the healthcare system, but they are also positioning suppliers favorably for the aftermath, says GlobalData, a leading data and analytics company. Organizations across various industries worldwide are pivoting in response to both the clinical and socio-economic effects of COVID-19 to help their local communities. For example, retailers are finding ways of dealing with high demand, […]
Read more

Intarcia’s ITCA 650 unlikely to reach diabetes market following second FDA rejection

Following the news that Intarcia has received a second rejection from the Food and Drug Administration (FDA) regarding its subcutaneous osmotic pump implant, ITCA 650, for type 2 diabetes (T2D) patients; Akash Patel MSc, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “This second FDA rejection leaves the future of Intarcia and its device highly uncertain and it is unlikely that its product will be able to reach the market. Even if ITCA 650 were to make it to market, […]
Read more
1 … 100 101 102 103 104 … 111